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The Journal of Immunology
B7h Triggering Inhibits the Migration of Tumor Cell Lines
Chiara Dianzani,* Rosalba Minelli,* Casimiro Luca Gigliotti,† Sergio Occhipinti,‡
Mirella Giovarelli,‡ Laura Conti,‡ Elena Boggio,† Yogesh Shivakumar,† Gianluca Baldanzi,x
Valeria Malacarne,x Elisabetta Orilieri,† Giuseppe Cappellano,† Roberto Fantozzi,*
Daniele Sblattero,† Junji Yagi,{ Jose` Maria Rojo,‖ Annalisa Chiocchetti,† and
Umberto Dianzani†
Vascular endothelial cells (ECs) and several cancer cells express B7h, which is the ligand of the ICOS T cell costimulatory molecule.
We have previously shown that B7h triggering via a soluble form of ICOS (ICOS-Fc) inhibits the adhesion of polymorphonuclear
and tumor cell lines to HUVECs; thus, we suggested that ICOS-Fc may act as an anti-inflammatory and antitumor agent. Because
cancer cell migration and angiogenesis are crucial for metastasis dissemination, the aim of this work was to evaluate the effect of
ICOS-Fc on the migration of cancer cells and ECs. ICOS-Fc specifically inhibited the migration of HUVECs, human dermal lym-
phatic ECs, and the HT29, HCT116, PC-3, HepG2, JR8, and M14 tumor cell lines expressing high levels of B7h, whereas it was
ineffective in the RPMI7932, PCF-2, LM, and BHT-101 cell lines expressing low levels of B7h. Furthermore, ICOS-Fc downmodu-
lated hepatocyte growth factor facilitated the epithelial-to-mesenchymal transition in HepG2 cells. Moreover, ICOS-Fc downmo-
dulated the phosphorylation of focal adhesion kinase and the expression of b-Pix in both HUVECs and tumor cell lines. Finally,
treatment with ICOS-Fc inhibited the development of lung metastases upon injection of NOD-SCID-IL2Rgnull mice with CF-
PAC1 cells, as well as C57BL/6 mice with B16-F10 cells. Therefore, the B7h2ICOS interaction may modulate the spread of cancer
metastases, which suggests the novel use of ICOS-Fc as an immunomodulatory drug. However, in the B16-F10–metastasized lungs,
ICOS-Fc also increased IL-17A/RORc and decreased IL-10/Foxp3 expression, which indicates that it also exerts positive effects on
the antitumor immune response. The Journal of Immunology, 2014, 192: 4921–4931.
B
7 homologoud protein (B7h, also known as B7H2,
B7-RP1, ICOSL, GL50, and CD275) belongs to the B7
family of surface receptors and it binds ICOS (CD278),
which belongs to the CD28 family (1–9). ICOS is selectively ex-
pressed by activated T cells, whereas B7h is expressed by a wide
variety of cell types, including B cells, macrophages, dendritic cells
(DCs), and a subset of T cells. However, B7h is also expressed by
cells of a nonhemopoietic origin such as vascular endothelial cells
(ECs), epithelial cells, and fibroblasts, as well as in many primary
tumors and tumor cell lines (10–12).
The main known function of B7h is the triggering of ICOS, which
functions as a costimulatory molecule for T cells by enhancing their
cytokine secretion (3, 13, 14), and in particular, the secretion of
IL-10, IL-17, IFN-g (in humans), IL-4 (in mice), and IL-21 (in both
species). The expression of B7h in nonlymphoid tissues, such as the
brain, heart, kidney, liver, and intestine, suggests that it regulates the
activation of Ag-experienced effector/memory T cells, which are
recruited to or reside within these peripheral tissues (15). However,
B7h expression also plays a role in secondary lymphoid tissue, par-
ticularly in the interaction between T and B cells; ICOS is expressed
at high levels by Th follicular cells, and ICOS deficiency has been
associated with the defective formation of lymphoid follicles in mice
and common variable immunodeficiency in humans (16).
Recent reports have shown that the B7h–ICOS interaction may
trigger bidirectional signals that can also modulate the response of
the cells expressing B7h. This B7h-mediated “reverse signaling” can
induce the partial maturation of immature mouse DCs with aug-
mentation of IL-6 secretion (17). In humans, we have found that B7h
triggering via ICOS-Fc, a recombinant soluble form of ICOS, sub-
stantially alters DC behavior by modulating the secreted cytokine
pattern, which promotes the capacity to cross-present endocytosed
Ags in class I MHC molecules and inhibits the adhesiveness to EC
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and the migratory response to chemoattractants (18). Moreover, we
showed that B7h stimulation inhibits the capacity of HUVECs to
adhere to several tumor cell lines and granulocytes (11). This in-
hibitory effect was similarly detected when B7h was triggered on
either HUVECs or the tumor cell lines and was accompanied by the
decreased phosphorylation of ERK and p38 in HUVECs only. This
indicated that the B7h–ICOS interaction modulates the recruitment
of granulocytes in inflammatory sites and the spread of cancer
metastases from the site of the primary tumor through the blood-
stream (11).
The aim of the research reported in this article was to extend
these observations by assessing the effect of B7h triggering on
other key issues of tumor growth. Tumor growth depends on the
proliferation and death rate of the tumor cells, metastasis dissemi-
nation depends on their capacity to migrate, and both tumor growth
and dissemination are favored by neoangiogenesis within the tumor
mass; thus, we assessed the effect of B7h triggering on the pro-
liferation, apoptosis, and migration of tumor cells and vascular
ECs. The results showed that B7h triggering strikingly inhibited
the migration activity of both tumor and ECs in vitro, which was
associated with the dephosphorylation of focal adhesion kinase
(FAK) and decreased b-Pix expression. However, B7h triggering
had no effect on their proliferation, apoptosis, or the ECs’ capacity
to form capillary-like structures. Moreover, B7h triggering ham-
pered tumor cell metastasis in vivo.
Materials and Methods
Cells
HUVECs were isolated from human umbilical veins via trypsin treatment
(1%) and cultured in M199 medium (Sigma-Aldrich, St. Louis, MO) with
the addition of 20% FCS (Invitrogen, Burlington, ON, Canada) and 100 U/ml
penicillin, 100 mg/ml streptomycin, 5 UI/ml heparin (Sigma-Aldrich),
12 mg/ml bovine brain extract, and 200 mM glutamine (Hyclone Labo-
ratories, South Logan, UT). HUVECs were grown to confluence in flasks
and used at the second to fifth passage. The purity of the ECs preparation
was evaluated using morphologic criteria and positive immunofluores-
cence for factor VIII. Contamination with blood leukocytes was assessed
via immunofluorescence with an anti-CD45 Ab. The use of HUVECs was
approved by the Ethics Committee of the ‘‘Presidio Ospedaliero Martini’’
of Turin and conducted in accordance with the Declaration of Helsinki.
Written informed consent was obtained from all donors. Human dermal
lymphatic ECs (HDLECs) were purchased from Promo Cell and cultured
with Endothelial Cell Growth Medium MV2 (Promo Cell GmbH, Hei-
delberg, Germany). The following human tumor cell lines were used:
HT29, HCT116 (colon adenocarcinoma), PC-3 (prostate carcinoma), CF-
PAC1 (human pancreas carcinoma), HepG2 (hepatic carcinoma), and B16-
F10 (murine melanoma) from the American Type Culture Collection
(ATCC; Manassas, VA); M14, JR8, RPMI7932, PCF-2, and LM (mela-
noma) from Dr. Pistoia (Gaslini Institute, Genoa, Italy); and BHT-101
(thyroid carcinoma) from Deutche Sammlung von Mikroorganismen and
Zellculturen (Braunschweig, Germany). The human tumor cell lines were
grown in culture dishes as a monolayer in RPMI 1640 medium (Invitrogen)
and DMEM (Invitrogen) for HepG2, CF-PAC1, BHT-101, and B16-F10
plus 10% FCS, 100 U/ml penicillin, and 100 mg/ml streptomycin at 37˚C
in a 5% CO2 humidified atmosphere.
The cells were treated or not treated with ICOS-Fc and F119SICOS-Fc, in
which the extracellular portion of human ICOS and its mutated form car-
rying a phenylalanine-to-serine substitution at position 119 (F119SICOS-Fc)
were cloned as fusion proteins to the human IgG1 Fc region (11).
The cell-surface phenotypes were assessed via direct immunofluorescence
and flow cytometry using the appropriate PE-conjugated anti-B7h mAb (R&D
Systems, Minneapolis, MN) and the appropriate FITC-, PE-, and allophyco-
cyanin-conjugated mAb to ICAM-1 (Biolegend, San Diego, CA), ICAM-2
(DiaClone Research, Manchester, U.K.), MadCAM (Abcam, Cambridge,
MA), CD31, CD62L, CD62E, CD62P (Immunotools, Friesoythe, Germany),
CD44v6–7 (Bender Med-Systems, Vienna, Austria), Sialyl Lewis X (Santa
Cruz Biotechnology, Dallas, TX), and VCAM-1 (eBiosciences, San Diego,
CA). The expression of Sialyl Lewis A was assessed via indirect immuno-
fluorescence using an appropriate mAb (Santa Cruz Biotechnology) and FITC-
conjugated goat anti-mouse Ig (Caltag Laboratories, Burlingame, CA). The
mean fluorescence intensity ratio (MFI-R) was calculated considering all of
the alive cells according to the following formula: MFI of the B7h-stained
sample histogram (arbitrary units)/MFI of the control histogram (arbitrary
units). The B16-F10 cells were split into two cell lines expressing high or low
levels of B7h (B7hhigh and B7hlow) via magnetic selection with PE-conjugated
anti-B7h mAb and anti-PE microbeads (Miltenyi Biotec, Bergisch Gladbach,
Germany).
Cell growth assays
In the MTT assay, the cells were normalized at 800 or 2500 cells/100 ml
in 96-well plates for HT29 or HUVECs, respectively. After an overnight
incubation, the medium was replaced with 100 ml culture medium with
0.5–4 mg/ml ICOS-Fc. In some experiments, the cells were refilled every
24 h with 4 mg/ml ICOS-Fc. After 24, 48, and 72 h of incubation, the
viable cells were detected via MTT (Sigma-Aldrich) at 570 nm, as de-
scribed by the manufacturer’s protocol. The absorbance of the controls
(i.e., the cells that received no drug) was normalized to 100%, and that
of the ICOS-Fc–treated cells was expressed as the percentage of the controls.
Eight replicate wells were used to determine each data point, and three
different experiments were performed.
In the colony-forming assay, cells (800/well) were seeded into six-well
plates and treated with the compounds. The mediumwas changed after 72 h,
and the cells were cultured for another 10 d. Subsequently, the cells were
fixed and stained with a solution of 80% crystal violet (Sigma-Aldrich) and
20% methanol (Sigma-Aldrich). The colonies were then photographed and
counted with Gel Doc equipment (Bio-Rad Laboratories, Hercules, CA).
In the cell death assay, the cells were incubated with and without either
etoposide (2 mg/ml; Sigma-Aldrich) or FCS for 18 h, and cell death was
then evaluated by counting the live cells with the trypan blue exclusion test
and detecting the dead cells upon cytofluorimetric analysis of the cells
stained with FITC-conjugated Annexin V (BD Biosciences, San Jose, CA)
and propidium iodide (Sigma-Aldrich).
Cell migration assays
In the Boyden chamber (BD Biosciences) migration assay, cells (8000) were
plated onto the apical side of 50 mg/ml Matrigel-coated filters (8.2-mm di-
ameter and 0.5-mm pore size; Neuro Probe; BIOMAP snc, Milan, Italy) in
serum-free medium with or without 2 mg/ml ICOS-Fc or F119SICOS-Fc.
Medium containing either 20% FCS or 10 ng/ml vascular endothelial
growth factor-A (VEGF-A; Sigma-Aldrich) or 50 ng/ml hepatocyte growth
factor (HGF; PeproTech, Rocky Hill, CT) was placed in the basolateral
chamber as a chemoattractant for the tumor, endothelial, or HepG2 cells,
respectively. The chamber was incubated at 37˚C under 5% CO2. After 8 h,
the cells on the apical side were wiped off with Q-tips. The cells on the
bottom of the filter were stained with crystal violet and counted (five fields for
each triplicate filter) with an inverted microscope (magnification 3100). The
results are expressed as the number of migrated cells per high-power field.
In the wound-healing experiments, the cells were plated onto six-well
plates (at a concentration of 106 cells/well) and grown to confluence. The
cells were then left for 12 h with FCS-free medium (to prevent cell prolif-
eration). The cell monolayers were carefully wounded by scratching with a
sterile plastic pipette tip along the diameter of the well. The cells were
washed twice with FCS-free medium and then incubated with culture me-
dium in the absence or presence of 2 mg/ml ICOS-Fc. Five fields of each of
the three wounds analyzed per condition were photographed immediately
after the scratch had been made (0 h) and 24 h later to monitor cell move-
ment into the wounded area.
In the cell scatter assay, the cells were plated on 24-well plates (2 3 104/
well HepG2, 3 3 104/well BHT-101) in 10% FCS and stimulated with the
indicated treatments. Phase-contrast images of random fields were acquired
(after 48 h for HepG2 and 24 h for BHT-101) with an Axiovert 40 CFL
microscope (Zeiss, Oberkochen, Germany) and analyzed with Image-Pro-
Plus software. For each experimental point, the length of at least 100 cells
and the percentage of disaggregated single cells were evaluated in 3 separate
images. For confocal microscopy, the cells were washed with PBS and fixed
in PBS containing 3% paraformaldehyde and 4% sucrose. The cells were
permeabilized in cold HEPES-Triton buffer (20 mM HEPES, 300 mM su-
crose, 50 mM NaCl, 3 mMMgCl2, 0.5% Triton X-100, pH 7.4). Intermediate
washing was performed with PBS containing 0.2% BSA. PBS containing 2%
BSA (Sigma-Aldrich) was used as a blocking reagent. Alexa Fluor 546
Phalloidin (Invitrogen) and TO-PRO3 (Invitrogen) were diluted in 2%
PBS-BSA and added directly onto each glass coverslip in a humidified
chamber for 30 min. Finally, each glass coverslip was washed briefly in water
and mounted onto a glass microscope slide using Mowiol resin (Sigma-
Aldrich, 20% Mowiol 4-88, 2.5% 1,4-diazabicyclo[2.2.2]octane in PBS, pH
7.4). Confocal images were acquired with a Leica confocal microscope TCS
SP2 equipped with LCS Leica confocal software (633 objective for HepG2
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or 403 objective for BHT-101; Leica Microsystems, Wetzlar, Germany).
Basal planes are shown.
Angiogenesis assays
In the tube-formation assay, HUVEC cells were seeded onto 24-well plates
(5 3 104/well) previously coated with 150 ml growth factor–reduced
Matrigel (BD Biosciences) in the presence of ICOS-Fc (2–4 mg/ml) or
control medium. The morphology of the capillary-like structures formed
by the HUVECs was analyzed after 15 h of culture using an inverted
microscope and was photographed with a digital camera. Tube formation
was analyzed with an imaging system (Image-Pro).
In the spheroid sprouting assay, ECs were coated onto Cytodex mi-
crocarriers and embedded in a fibrin gel. Factor X, which was extracted
from confluent fibroblasts medium, was added to the medium to promote
ECs sprouting from the surface of the beads. After 4–5 d, numerous vessels
could be observed with a phase-contrast microscope. The newly formed
vessels were then treated or not treated with ICOS-Fc (4 mg/ml), and
vessel morphology was analyzed 5 d later.
Western blot analysis
The cells were lysed in a buffer composed of 50 mM Tris-HCl pH 7.4,
150 mM NaCl, 5 mM EDTA, 1% nonyl phenoxypolyethoxylethanol 40,
and phosphatase and protease inhibitor cocktails (P2850, P8340; Sigma-
Aldrich). The tissues were lysed in a buffer composed of 160 mM NaCl,
20 mM Tris-HCl pH 7.4, 1 mM EDTA, 1 mM EGTA, 1% Triton X-100, 1%
sodium deoxycholate, and 0.1% SDS. The lysates were then cleared of
insoluble fractions through high-speed centrifugation, and the protein
concentrations were determined with a commercially available kit (Bio-Rad
Laboratories). Then 40 mg proteins were loaded on 10% SDS PAGE gels,
and after electrophoresis, transferred onto Hybond-C extra nitrocellulose
membranes (Ge Healthcare, Piscataway, NJ). These were blocked for 1 h
at room temperature with 5% nonfat milk dissolved in TBST. The
membranes were then probed overnight with Abs to b-Pix (SH3 domain;
Millipore, Billerica, MA), phospho-FAK (Y397; Cell Signaling Technol-
ogy, Danvers, MA), FAK (BD Biosciences), b-actin (A1978; Sigma-
Aldrich), and after 3 washes, incubated for 1 h with HRP-conjugated
secondary Abs (GE Healthcare, Piscataway, NJ). The bands were detected
via chemiluminescence, and densitometric analysis was performed using
Multi-Analyst software (version 1.1; Bio-Rad Laboratories).
In vivo experiments
Female 4- to 5-wk-old NOD-SCID-IL2Rgnull (NSG; The Jackson Labo-
ratory, Bar Harbor, ME) mice were bred under pathogen-free conditions in
the animal facility of the Molecular Biotechnology Center, University of
Turin, and were treated in accordance with the University Ethical Com-
mittee and European guidelines. The mice were injected in the tail vein
with stably expressing firefly luciferase (Luc) CF-PAC1 (human pancreas
carcinoma) cells (0.5 3 106/mouse) and monitored for pulmonary me-
tastases after 3 d via in vivo optical imaging. In each experiment, the mice
were treated every day via the i.p. injection of either human ICOS-Fc plus
mouse ICOS-Fc, human ICOS-Fc alone, mouse ICOS-Fc alone, human
F119SICOS-Fc alone (100 mg each), or the same volume of PBS as a con-
trol. Three days after tumor cell injection, the mice were injected i.p. with
150 mg/Kg luciferin (Perkin Elmer, Waltham, MA) in sterile PBS. They
were then placed in the IVIS 200 (Perkin Elmer) induction chamber and
subjected to inhalational isoflurane anesthesia (Abbott, Abbott Park, IL) at
2.5% with 1 l/min flow of oxygen. After 10 min, the mice were placed on
the heated imaging platform of the IVIS 200 imaging station with inha-
lational isoflurane anesthesia during the imaging procedure. White light
and Luc activity images were acquired with a 25-s exposure. The images
FIGURE 1. B7h expression in endothelial and tumor cell lines. B7h expression was assessed in the HUVEC, HDLEC, JR8, M14, PC-3, HT29, HCT116,
RPMI7932, PCF-2, LM, and BHT-101 cell lines via flow cytometry using an anti-B7h mAb. The numbers in each panel indicate the MFI-R. The cutoff
between the B7hhigh and B7hlow cells was set at MFI-R = 2.
The Journal of Immunology 4923
 by guest on February 2, 2017
http://w
w
w
.jimmunol.org/
D
ow
nloaded from
 
were analyzed with the Living Image software (PerkinElmer). The lumi-
nescent signal was quantified as the average radiance (p/s/cm2/sr) mea-
sured in the regions of interest drawn in the lungs.
Female 5- to 7-wk-old C57BL/6 mice (Harlan Laboratories, Indian-
apolis, IN) were injected in the tail vein with B7hhigh B16-F10 cells (106
cells/mouse) and then treated daily with an i.p. injection of either the
mouse ICOS-Fc, the human F119SICOS-Fc (100 mg each), or the same
volume of PBS as a control. Two weeks after cell injection, the mice were
euthanized, and the number of metastases detectable in the lung surfaces
was evaluated by two blinded observers. In some experiments, the mice
were euthanized 3 d after cell injection, and the metastases were counted in
fixed sections of the lungs stained with H&E (Sigma-Aldrich).
The infiltrating cells were obtained by grinding the fresh lungs, obtained
at day 3, through a 100-mm cell strainer mesh (BD Biosciences); the total
RNA was then isolated using TRIzol reagent (Invitrogen). RNA (500 ng)
was retrotranscribed using the ThermoScript RT PCR System (Invitrogen).
IL-17A, IL-10, IL-21, RORc, Foxp3, and Bcl6 expression were evaluated
with a gene expression assay (Assay-on Demand; Applied Biosystems,
Foster City, CA). The b-glucuronidase gene was used to normalize the
cDNA amounts. Real-time PCR was performed using the CFX96 System
(Bio-Rad Laboratories) in duplicate for each sample in a 10 ml final vol-
ume containing 1 ml diluted cDNA, 5 ml TaqMan Universal PCR Master
Mix (Applied Biosystems), and 0.5 ml Assay-on Demand mix. The results
were analyzed with a D-D threshold cycle method.
In other experiments, the C57BL/6 micewere injected s.c. with 106B7hhigh
B16-F10 cells. When the tumor diameter reached 4 mm, the mice received
an intratumoral injection of the mouse ICOS-Fc, humanF119SICOS-Fc
(100 mg each), or the same volume of PBS as a control. After 30 min, the
tumors were excised and immediately frozen in liquid nitrogen for Western
blot analyses.
Data analysis
The data are shown as the mean 6 SEM. The statistical analyses were
performed with GraphPad Prism 3.0 software using one-way ANOVA and
Dunnett’s test (GraphPad Software, San Diego, CA).
Results
B7h triggering has no effect on cell proliferation and apoptosis
To assess the effect of B7h triggering (via ICOS-Fc) on the prolifer-
ation, apoptosis, andmigration of the tumor cells and vascular ECs,we
used two primary EC lines (HUVECs and HDLECs) and nine con-
tinuous tumor cell lines (HT29 and HCT116 [colon carcinoma], PC-3
[prostate carcinoma],M14, JR8, RPMI7932, PCF-2, LM [melanoma],
and BHT-101 cells [thyroid carcinoma]). The surface immunofluo-
rescence and flow cytometry showed that B7h was expressed in
all cell lines and at high levels (B7hhigh) in HUVECs, HDLECs,
JR8, M14, PC-3, HT29, and HCT116, but low levels (B7hlow) in
BHT-101, RPMI7932, PCF-2, and LM (Fig. 1).
Initially, the effect of ICOS-Fc on cell proliferation and death
was assessed in HUVECs, HT29, and PC-3, which expressed high
levels of B7h. In the proliferation assay, the cells were cultured in
the presence of various concentrations of ICOS-Fc (0.5–4 mg/ml)
for 24–96 h, and cell proliferation was then assessed via the MTT
and the clonogenic assays. The results showed that ICOS-Fc did
not modulate cell proliferation in any cell line at any dose or time
FIGURE 2. The effect of ICOS-Fc on the motility of the endothelial and tumor cell lines as assessed via a Boyden chamber assay. Cells: (A) HUVEC and
HDLEC; (B) HT29, HCT116, PC-3, M14, and JR8; (C) RPMI7932, PCF-2, LM, and BHT-101 were plated onto the apical side of Matrigel-coated filters in
50 ml medium in the presence or absence of either 2 mg/ml ICOS-Fc or F119SICOS-Fc; either VEGF-A (10 ng/ml) or 20% FCS was loaded in the basolateral
chamber as chemotactic stimulus. The cells that migrated to the bottom of the filters were stained using crystal violet and counted (five fields for each
triplicate filter) using an inverted microscope. The data are expressed as the mean 6 SEM (n = 5) of the number of migrated cells per high-power field
(*p , 0.05, **p , 0.01 versus the control).
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(data not shown), even when the ICOS-Fc was refilled every 24 h.
In the cell death assay, the cells were cultured for 18 h in the
presence or absence of ICOS-Fc (2 mg/ml) either in the absence of
FCS (to induce cell death by neglect) or in the presence of eto-
poside. Then cell survival was assessed after 18 h by counting the
surviving cells with the trypan blue exclusion test, and the dead
cells were evaluated by staining with propidium iodide and FITC-
conjugated Annexin V followed by cytofluorimetric analysis. The
results showed that ICOS-Fc did not induce cell death and did not
modulate either cell death by neglect or that induced by etoposide
in any cell line (data not shown).
B7h triggering inhibits cell migration and the epithelial-to-
mesenchymal transition
To evaluate the effect of ICOS-Fc on cell migration, we seeded
the endothelial and the tumor cell lines in the upper chamber of
a Boyden chamber in serum-free medium in the presence or ab-
sence of ICOS-Fc (2 mg/ml) and allowed them to migrate for 8 h
toward the lower chamber containing medium supplemented or
not supplemented with either VEGF-A (10 ng/ml) or 20% FCS,
which were used as chemoattractants for the endothelial and the
tumor cells, respectively. As a control, the same experiments were
performed in the presence of F119SICOS-Fc, a mutated form of
ICOS-Fc carrying a phenylalanine-to-serine amino acid substitu-
tion at position 119 that is unable to bind B7h. The results showed
that ICOS-Fc significantly inhibited cell migration by ∼50–70%
in all of the B7hhigh cell lines (i.e., HUVECs, HDLECs, HT29,
HCT116, PC-3, M14, and JR8) in both the presence and the ab-
sence of the chemoattractants (Fig. 2A, 2B). This effect was
specific because it was not exerted by F119SICOS-Fc. In contrast,
neither ICOS-Fc nor F119SICOS-Fc exerted any effect on the
B7hlow cell lines (i.e., RPMI7932, PCF-2, LM, and BHT-101),
which indicated that the inhibitory effect was B7h mediated
(Fig. 2C).
To confirm the effect of ICOS-Fc on directional cell migration,
we performed the scratch assay, an in vitro “wound healing” assay,
on PC-3, HT29, and HUVECs, because cell migration is highly
efficient for PC-3, poor for HT29, and intermediate for HUVECs
in this assay. A linear scratch was performed on a confluent
monolayer of each cell line, and they were then cultured in FCS-
free medium to minimize cell proliferation in the presence or
absence of ICOS-Fc (2 mg/ml). A microscopic analysis evaluating
cell capacity to migrate and fill the empty areas at different times
showed that in the absence of ICOS-Fc, substantial cell migration
was detectable in the wound area for PC-3 and HUVECs, and that
it was substantially inhibited by ICOS-Fc (Fig. 3). This inhibition
was also detectable for HT29 cells, which displayed a low mi-
gratory activity that was detectable as a fringing of the scratch
edges after the 24-h incubation; this pattern was substantially
inhibited by ICOS-Fc.
To assess the effect of ICOS-Fc on the epithelial-to-mesenchymal
transition (EMT), we performed a scatter assay to treat the HepG2
cells (hepatic carcinoma) with HGF. In cultures, these cells grow
as colonies that maintain an epithelial morphology; however,
they break down cell junctions and acquire an elongated mesen-
chymal phenotype upon HGF/scatter factor treatment (19). A cyto-
fluorimetric analysis showed that these cells express high levels of
B7h (Fig. 4A). The cells were treated for 72 h in 10% FCS with or
without HGF (50 ng/ml) and in the presence or absence of either
ICOS-Fc (2 mg/ml) or F119ICOS-Fc (2 mg/ml). They were then
directly analyzed via phase-contrast microscopy (Fig. 4B, left
panel) or stained with Alexa Fluor 546 Phalloidin and imaged via
confocal microscopy (Fig. 4B, right panel). The results showed that
ICOS-Fc substantially inhibited the cell scatter induced by HGF by
FIGURE 3. Effect of ICOS-Fc on the mo-
tility of the PC-3, HT29, and HUVECs as
assessed using a “wound-healing” assay. The
cells were grown to confluence on six-well
plates. A scratch was made through the cell
layer using a pipette tip; the cells were washed
and then cultured in the presence or absence
of 2 mg/ml ICOS-Fc for 24 h. Microphoto-
graphs of the wounded area were taken imme-
diately after the scratch was made (0 h) and
24 h later to monitor cell migration into the
wounded area (original magnification310).
Panels show a representative experiment from
three experiments.
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impairing the acquisition of the elongated mesenchymal mor-
phology (median length of ICOS-Fc–untreated versus –treated cells:
60 mm versus 31 mm; Fig. 4C) and promoting the maintenance
of colonies with cell-to-cell junctions and smooth borders with
decreased numbers of disaggregated single cells (Fig. 4D). We
also assessed the effect of ICOS-Fc on the migration of HepG2
cells induced by HGF (50 ng/ml) in the Boyden chamber assay.
In accordance with the previous results, ICOS-Fc, but not
F119SICOS-Fc, inhibited the stimulated migration of HepG2 by
∼50% (Fig. 4E). To assess whether these effects were depen-
dent on B7h expression, we evaluated the effect of ICOS-Fc and
F119SICOS-Fc on the HGF-induced cell scattering of BHT-101,
which was previously shown to express low levels of B7h (Fig. 1)
and to display no ICOS-Fc–induced migration inhibition (Fig. 2).
Because these cells showed modest elongation upon HGF treatment,
their scattering was quantified only by counting the percentage of
disaggregated single cells. The results showed that neither ICOS-Fc
nor F119SICOS-Fc inhibited BHT-101 cell scattering (Supplemental
Fig. 1).
B7h triggering has no effect on angiogenesis
To assess the effect of B7h triggering on angiogenesis, we eval-
uated the effect of ICOS-Fc via the endothelial tube-formation
assay and the spheroid sprouting assay. In the tube-formation
assay, HUVECs were seeded onto 24-well plates (5 3 104/well)
previously coated with 150 ml growth factor–reduced Matrigel in
the presence of ICOS-Fc (2–4 mg/ml) or control medium. The
morphology of capillary-like structures formed by HUVECs was
analyzed 15 h after culturing. The results showed that ICOS-Fc
did not significantly affect tube formation in HUVECs (data not
shown).
In the spheroid sprouting assay, ECs were coated onto Cytodex
microcarriers and embedded in a fibrin gel in the presence of
factor X to promote EC sprouting from the surface of the beads.
After 4–5 d, the newly formed vessels were treated or not treated
with ICOS-Fc (4 mg/ml); vessel morphology was analyzed 5 d
later. The results showed that ICOS-Fc did not significantly affect
vessel caliper or length (data not shown).
B7h triggering inhibits b-Pix expression and FAK
phosphorylation
To assess whether treatment with ICOS-Fc modulated the ex-
pression of adhesion molecules, we analyzed the surface expres-
sion of ICAM-1, ICAM-2, MadCAM, CD62P, CD31, CD44v6–7,
CD62E, Sialyl Lewis A, CD62L, VCAM-1, and Sialyl Lewis X
via immunofluorescence and flow cytometry in JR8, M14, and
HT-29 cells treated or untreated with ICOS-Fc for 30 min, 1, 4,
and 24 h. The results showed that ICOS-Fc did not modulate the
expression of any of these molecules (data not shown), which is in
accordance with previous data obtained for HUVECs and DCs
(11, 18).
In previous studies, we have shown that B7h triggering inhibits
the phosphorylation of p38 and ERK induced by either E-selectin
triggering or osteopontin in HUVECs (this occurred without af-
fecting their basal phosphorylation), whereas no effect was de-
tected in the tumor cell lines (11). Moreover, we showed that in
FIGURE 4. ICOS-Fc impairs HGF-induced cell scatter in HepG2 cells. (A) Cytofluorimetric analysis of the B7h expression in the HepG2 cells (per-
formed as in Fig. 1). The HepG2 cells were treated for 48 h in 10% FCS with or without HGF (50 ng/ml), ICOS-Fc (2 mg/ml), or F119SICOS-Fc (2 mg/ml).
(B) The cells were photographed via phase contrast (left panel) or stained with Alexa Fluor 546 Phalloidin and imaged via confocal microscopy (right
panel). Scale bar, 40 mm. (C) Whisker plot showing the cell length (excluding the outliers of a representative experiment). (D) Percentage of the dis-
aggregated single cells (mean 6 SEM of 4 experiments); at least 100 cells were counted for each point. (E) Effect of ICOS-Fc on the migration of HepG2
cells treated with HGF in the Boyden chamber assay (performed as in Fig. 2). *p , 0.05, **p , 0.01, ***p , 0.001.
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DCs, B7h inhibits the expression of the Rac-1 activator b-Pix,
which is involved in cell motility (18). Therefore, we evaluated the
effect of ICOS-Fc on the b-Pix expression in two B7hhigh cell
lines (PC-3, HUVECs) and two B7hlow cell lines (RPMI7932,
BHT-101), and extended the analysis to the phosphorylation of
FAK, involved in cell migration. The cells were either not treated
or were treated with ICOS-Fc or F119SICOS-Fc; b-Pix expression
and FAK phosphorylation were then assessed via Western blot
after 30 min. The results showed that ICOS-Fc substantially de-
creased b-Pix expression and FAK phosphorylation in the B7hhigh
cell lines (Fig. 5A, 5B), whereas no effect was detected in the
B7hlow cell lines (Fig. 5C, 5D). The treatment with F119SICOS-Fc
showed no effect for any cell line.
B7h triggering inhibits tumor cell metastasis in vivo
The effect of B7h triggering on the metastasis capability in vivo was
assessed by injecting NSG mice with CF-PAC1 Luc cells (human
pancreas carcinoma). A previous in vitro analysis showed that this
cell line expresses high levels of B7h (Fig. 6A) and that its treatment
with ICOS-Fc, but not with F119SICOS-Fc, inhibits migration in the
Boyden chamber assay (Fig. 6B), as well as b-Pix expression and
FAK phosphorylation (Fig. 6C); these findings are in accordance
with the data obtained for the other B7hhigh cell lines.
NSG mice were i.v. injected with 0.5 3 106 CF-PAC1 Luc cells
and then i.p. treated with both the human and the mouse ICOS-Fc
(n = 7) or PBS (n = 7) every day to trigger both the B7h expressed
by the human tumor cell line and that expressed by the mouse
vascular ECs; this treatment would mimic the putative effect of
the human ICOS-Fc injected in humans. Three days after cell
injection, the mice were i.p. injected with luciferin and analyzed
via in vivo optical imaging to evaluate the tumor cell growth in the
lung. Qualitative (Fig. 6D) and quantitative (Fig. 6E) analyses
showed that a significantly higher luminescent signal was present
in control mice than in those treated with ICOS-Fc. To determine
whether this effect was due to the human or mouse ICOS-Fc, we
repeated these experiments by treating the mice with either the
human ICOS-Fc alone (n = 3), the mouse ICOS-Fc alone (n = 3),
the human F119SICOS-Fc alone (n = 3), or PBS (n = 3). The
qualitative (Fig. 6F) and quantitative (Fig. 6G) analyses showed
that a significantly higher luminescent signal was present in the
control mice and those treated with F119SICOS-Fc than in mice
treated with either the human or mouse ICOS-Fc alone. In con-
trast, no significant differences were detected between the control
mice and those treated with F119SICOS-Fc.
To confirm these data, we assessed the ICOS-Fc effect on the
metastasis of B16-F10 cells (mouse melanoma) in C57BL/6 mice.
In a preliminary experiment, we separated the B7hhigh and B7hlow
B16-F10 cells using magnetic beads and found that these cell lines
maintained their phenotype for several weeks in culture. Moreover,
treatment with ICOS-Fc, but not with F119SICOS-Fc, inhibited mi-
gration in Boyden chamber assay, as well as b-Pix expression and
FAK phosphorylation in the B7hhigh cell line, whereas no effects
were detected in the B7hlow cell line (Supplementary Fig. 2).
The C57BL/6 mice were i.v. injected with 106 B7hhigh B16-F10
cells and then i.p. treated with either the mouse ICOS-Fc (n = 3),
human F119SICOS-Fc (n = 3), or PBS (n = 3) every day. The lung
metastases were analyzed either after 3 d (for the tissue sections
stained with H&E) or after 2 wk by counting the tumor nodules
FIGURE 5. Effect of ICOS-Fc on FAK phosphorylation and b-Pix expression in the B7hhigh (PC-3, HUVEC) and B7low (RPMI7932, BHT-101) cell
lines. The cell lines were treated with 4 mg/ml ICOS-Fc or F119SICOS-Fc for 30 min; p-FAK (A and C) and b-Pix (B and D) expression were then evaluated
via Western blot in the cell lysates. The same blots were also probed with anti-FAK or anti–b-actin Ab as a control. The bar graphs show the densitometric
analysis of the gels expressed in arbitrary units; data are expressed as the mean 6 SEM of the percentage of inhibition versus the control from three
independent experiments (**p , 0.01 versus the control).
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detectable on the lung surface. Both approaches showed that the
mice treated with the mouse ICOS-Fc displayed significantly
fewer metastases than those treated with either PBS or the human
F119SICOS-Fc (Fig. 7A, 7B). To determine whether the treatments
modulated the immune response, we obtained infiltrating cells
from the lungs, and we evaluated the mRNA levels of IL-17A and
RORc (marking Th17 cells), IL-10 and Foxp3 (marking regulatory
T cells [Tregs]), and IL-21 and Bcl6 (marking T follicular helper
cells) via real-time PCR (because ICOS has a key role in Th17,
Treg, and T follicular helper cell function) (3, 13–15). The results
showed that treatment with the mouse ICOS-Fc significantly in-
creased the expression of IL-17A and RORc, and decreased that of
IL-10 and Foxp3 compared with the levels detected in control
mice and those treated with the human F119SICOS-Fc (Fig. 7C). In
contrast, no differences were detected in the expression of Bcl6,
whereas IL-21 was always undetectable (data not shown). More-
over, ICOS-Fc did not modulate the expression of these molecules
in the control mice not injected with the B16-F10 cells; in these
mice, Foxp3 and Bcl6 were expressed at low levels, whereas IL-
17A, RORc, IL-10, and IL-21 were undetectable (data not shown).
To assess whether treatment with ICOS-Fc decreased b-Pix
expression and FAK phosphorylation in vivo, the C57BL/6 mice
were injected s.c. with 106 B7hhigh B16-F10 cells. When the tumor
diameter reached 4 mm, the mice received one intratumor injec-
tion of either the mouse ICOS-Fc, human F119SICOS-Fc, or the
same volume of PBS. After 30 min, the tumors were excised, and
b-Pix expression and FAK phosphorylation were assessed in the
tissue lysates via Western blot. The results showed that treatment
with ICOS-Fc, but not with F119SICOS-Fc, substantially decreased
the expression of b-Pix compared with that detected in the control
mice (Fig. 7D). The FAK expression was similar in all conditions,
and the phospho-FAK expression was always undetectable (data
not shown).
Discussion
Cancer progression involves a complex interplay between the tu-
mor and the microenvironment that results in sustained proliferative
signaling, resistance to cell death, as well as the promotion of an-
giogenesis, invasion, and metastasis (20–23). This work has shown
that ICOS binding to B7h influences several of these events by acting
on both ECs and tumor cells. These effects were specific; they were
not displayed by a mutated form of ICOS-Fc that was incapable of
binding B7h.
Themost striking effect was that on tumor cells: ICOS-Fc inhibited
EMT and migration in vitro, as well as metastasis in vivo. EMT is
a transdifferentiation program required for tissue morphogenesis
during the embryonic development; its induction is exploited by
cancer cells to acquire invasive and metastatic properties. Recent
FIGURE 6. Effects of B7h triggering on CF-PAC1 tumor cell metastasis in vivo. (A) Cytofluorimetric analysis of B7h expression in the CF-PAC1 Luc
cells (performed as in Fig. 1). (B) Effect of ICOS-Fc on the migration of the CF-PAC1 Luc cells in the Boyden chamber assay (performed as in Fig. 2). (C)
Effect of ICOS-Fc on the expression of p-FAK and b-Pix (performed as in Fig. 5). (D and E) Mice were injected i.v. with 0.53 106 CF-PAC1 Luc cells and
treated with the human ICOS-Fc plus mouse ICOS-Fc (n = 7) or PBS (control group, n = 7). (F and G) The mice injected with CF-PAC1 Luc were treated
with either the human ICOS-Fc (n = 3), mouse ICOS-Fc (n = 3), human F119SICOS-Fc (n = 3), or PBS (control group, n = 3). After 3 d, the mice were i.p.
injected with luciferin, and pulmonary metastases were macroscopically detectable and documented via in vivo optical imaging. The luminescent signal
was quantified as the average radiance (p/s/cm2/sr), which was measured in regions of interest drawn in the lungs. Data are expressed as the mean 6 SEM
and were obtained in two independent experiments (*p , 0.05, **p , 0.01).
4928 B7h TRIGGERING INHIBITS TUMOR CELL MIGRATION
 by guest on February 2, 2017
http://w
w
w
.jimmunol.org/
D
ow
nloaded from
 
reports indicate that EMT is also involved in the emergence of cancer
stem cells and contributes to drug resistance (24). A classical inducer
of EMT is HGF (also known as scatter factor), which promotes an
“invasive growth” of epithelial cells that is characterized by the
disruption of intercellular contacts and the induction of cell motility,
survival, and proliferation (19, 25). Our experiments on HepG2 cells
show that ICOS-Fc effectively impairs their HGF-induced scattering
by preserving the epithelial morphology and strongly reducing the
HGF-induced migration. These findings suggest that ICOS-Fc could
also affect EMT in vivo and decrease the metastatic potential of
tumor cells.
To successfully metastasize (after the downregulation of cell-to-
cell junctions and the acquisition of a migratory phenotype), tumor
cells must invade the extracellular matrix and intravasate; they will
then disseminate and become sites of origin for future metastases.
Cell movement across the tissues plays a crucial role in several of
these steps. Thus, a major aim in modern cancer therapy strategies
is to counteract metastatic spreading by targeting the factors in-
volved in the migratory activity of tumor cells. This has been
mainly achieved using antagonists of the molecules involved in the
adhesion of these cells to the extracellular matrix (26), as well as
antagonists of proteases that facilitate cell migration by degrading
the extracellular matrix (27–29). Unfortunately, none of these
compounds has yet reached the market, primarily because of poor
in vivo antitumor activity, unsuitable therapeutic index, or the
rapid development of chemoresistance. This work suggests that
B7h may be a novel target for these therapies because ICOS-Fc
inhibits the migration of several tumor cell lines in vitro. This
effect is not ascribable to drug toxicity because the proliferation
and survival of tumor cells are not affected by ICOS-Fc. More-
over, this effect is specific; it is not detected in tumor cell lines
expressing low levels of B7h.
This underlines a potential pharmacological limitation of
ICOS-Fc, the efficacy of which is expected to be restricted to B7hhigh
tumors. It is intriguing that the migratory response to FCS
appeared to be weaker in the B7hlow than in the B7hhigh cell lines
and that the B7hlow B16-F10 cells displayed lower migratory ac-
tivity than their B7hhigh counterparts, which suggests that B7h may
play a direct role in cell migration. The antimetastatic effect of
ICOS-Fc is supported by our in vivo experiments showing that
treatment with ICOS-Fc inhibits the migration of both a human
(CF-PAC1 Luc) and a mouse (B16-F10) tumor cell line into the
lungs in mice. It is noteworthy that this effect was induced by both
the human and the mouse ICOS-Fc in the CF-PAC1 Luc human/
mouse model, which indicates that the effect was ascribable to the
triggering of both varieties of B7h on the tumor cells, as well as
the ECs. The human ICOS-Fc does not bind the mouse B7h, and the
mouse ICOS-Fc weakly binds the human B7h (data not shown).
These data strengthen those obtained from previous research
showing that ICOS-Fc inhibits tumor cell adhesion to ECs by acting
on both the tumor cells and the ECs (11). Moreover, in the B16-F10
model, treatment with ICOS-Fc increased the expression of IL-
17A and RORc, and decreased the expression of IL-10 and Foxp3;
this suggests that ICOS-Fc may also exert positive effects on the
antitumor immune response by increasing the Th17/Treg ratio.
This observation is in accordance with reports showing that the
triggering of B7h in immature mouse DCs induces partial matu-
ration with the prominent augmentation of IL-6 secretion (17), as
FIGURE 7. Effect of B7h triggering on B16-F10 cells in vivo. (A and B) Effect on metastasis in C57BL/6 mice injected in the tail vein with 106 B7hhigh
B16-F10 cells and treated daily with either the mouse ICOS-Fc (n = 3), human F119SICOS-Fc (n = 3), or the same volume of PBS (control group, n = 3). The
lung metastases were analyzed either after 3 d (on tissue sections stained with H&E) (A) or after 2 wk by counting the detectable tumor nodules on the lung
surface (B); (C) infiltrating cells from the 3-d experiment were harvested and used for the real-time PCR analysis of IL-17A, IL-10, RORc, and Foxp3
expression; the data are normalized for the expression in the control mice (control expression set at 100%). (D) Effect on b-Pix expression in s.c. tumors
treated with an intratumoral injection of either the mouse ICOS-Fc, human F119SICOS-Fc, or the same volume of PBS. The C57BL/6 mice were s.c. injected
with 106 B7hhigh B16-F10 cells, and the tumors were treated when they reached 4 mm in diameter. The b-Pix expression was evaluated via Western blot in
the lysates of the tumor tissue. The data are expressed as the mean 6 SEM and were obtained from three experiments (*p , 0.05, **p , 0.01).
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well as reports indicating that IL-6 supports the conversion of
Foxp3+CD4+ Tregs to Th17 cells (30). Moreover, we found that
B7h triggering in human DCs increases the secretion of IL-23
(which is involved in Th17 expansion and survival) and supports
Th17 cell activity (18). Finally, ICOS triggering in T cells (which
is blocked by ICOS-Fc) is involved in the differentiation of both
Tregs and Th17 cells (17, 31–33); however, its support of Treg
differentiation prevails in the tumor environment (34, 35).
The possibility that ICOS-Fc may also affect tumor angiogenesis
is suggested by the finding that it substantially inhibits the mi-
gration of vascular ECs. However, it does not inhibit EC prolif-
eration or angiogenesis, as determined via the tubulogenesis and
the sprouting assays, which indicates that the residual migratory
potential of ECs is sufficient for these in vitro assays. However, this
does not rule out the possibility that ICOS-Fc may be effective
in limiting conditions in vivo. The antiangiogenic potential of
ICOS-Fc is intriguing because the survival of the primary tumor
beyond a certain size requires neovascularization of the tumor
mass, and tumor-associated vessels represent a preferential path-
way for metastasization to distant sites. Thus, controlling tumor-
associated angiogenesis may limit cancer progression (21). How-
ever, clinical results from studies using individual antivascular
agents have been unsatisfactory and have required the combina-
torial use of conventional anticancer drugs and antivascular agents
(22). Therefore, novel antivascular agents targeting B7h would be
welcome in antitumor therapy.
In previous works, we demonstrated that B7h triggering inhibits
the activation of the ERK and p38 axis induced in ECs via various
proadhesive stimuli. This leads to cytoskeleton modifications with
the disruption of the VE-cadherin/b-catenin complex and the for-
mation of stress fibers involved in increasing the endothelial per-
meability and enabling the transendothelial migration of cancer cells
(11). However, this is not a general effect because it was not detected
in tumor cell lines (11) or DCs (18). In contrast, in DCs (18), ECs,
and tumor cells (Fig. 6), ICOS-Fc downregulates the expression
of b-Pix, which is a Rac-1 activator that is recruited by activated
integrins and is required for rapid nascent adhesion turnover.
Intriguingly, the downregulation of b-Pix expression is known to
prevent cell spreading and lamellipodial formation, and to increase
Rac1 activity (36, 37). Moreover, in ECs and tumor cells, B7h
triggering inhibits the phosphorylation of FAK, which is a key
mediator of signaling through integrins. The overexpression and
activation of FAK have been found in a variety of human cancers
and have been involved in cancer migration, invasion, EMT, and
angiogenesis (38). FAK signaling has also been shown to promote
angiogenesis in both embryonic development and tumor angio-
genesis, and the increased phosphorylation and activation of FAK
have been correlated with increased EC migration into wounded
monolayers (39). The signaling pathways activated by B7h are
presently unknown. In DCs, the engagement of B7.1 or B7.2 with
CTLA4-Ig leads to the STAT-1–mediated production of IDO and
decreased tryptophan levels (40, 41); however, it is unclear whether
a similar signaling pathway is also activated by B7h.
Upon extrapolating these data to physiological conditions, it may
be suggested that the physiological role of B7h-mediated signal-
ing is based on its effect on invasion, which is involved not only in
tumor progression (42), but also in tissue remodeling during
embryonic development, wound healing, angiogenesis, and im-
mune responses. In accordance with this possibility, the repair of
excisional wounds was dramatically delayed in mice deficient in
either ICOS or B7h; these mice showed decreased keratinocyte
migration, angiogenesis, granulation tissue formation, and dimin-
ished infiltration of T cells, macrophages, and neutrophils (43). One
possibility is that B7h+ cells, which are recruited from the blood
and the surrounding tissues for tissue defense and repair, are
arrested in the injured tissue via B7h interacting with the ICOS
that is expressed by the infiltrating T cells. Therefore, a defective
B7h–ICOS interaction may eventually affect the accumulation of
infiltrating cells in the injured tissue.
In conclusion, our data indicate that ICOS-Fcmay be an effective
antimetastasis drug acting on ECs and tumor cells both in vitro and
in vivo. Therefore, ICOS-Fc (which affects cancer cell migration
without severe toxic effects) may be a sound tool in cancer therapy
that acts on several aspects of tumor progression.
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FIGURE S1: ICOS-Fc does not affect HGF induced cells scatter in BHT-101.Cells were treated for 
24 h with or without HGF (50 ng/ml), ICOS-Fc (2 µg/ml) or F119SICOS-Fc (2 µg/ml). (A) Cells were 
photographed by phase contrast (left panel) or stained with Phalloidin-Alexa-Fluor 546 (red) / TO-
PRO 3 (blue) (right panel) and imaged by confocal microscopy. Scale bar 40 µm. (B) Percentage of 
disaggregated single cells (mean±SEM of 4 experiments); at least 100 cells were counted for each 
point (* P< 0.01 ). 
FIGURE S2: Effect of ICOS-Fc on B7hhigh and B7hlow B16-F10 cells in vitro. (A, D) 
Cytofluorimetric analysis of B7h expression performed as in Fig. 1. (B, E) Effect of ICOS-Fc on 
cell migration in the Boyden chamber assay performed as in Fig. 2. (C, F ) Effect of  ICOS-Fc on 
FAK phosphorylation (left panel) and β-Pix expression (right panel) performed as in Fig. 5. Data 
are expressed as mean±SEM from 3 independent experiments (** P<0.01, * P<0.05 versus the 
control). 
 
